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1 These two authors contributed equally to this worThe exact role of the central acidic domain of Mdm2 in p53 degradation remains unclear. We there-
fore performed a systematic and comprehensive analysis of the acidic domain using a series of short
deletions and found that only a minor part of the domain was indispensable for Mdm2-mediated
p53 ubiquitylation. Moreover, we identiﬁed a short stretch of acidic amino acids required for p53
degradation but not ubiquitylation, indicating that, in addition to p53 ubiquitylation, the acidic
domain might be involved in a critical post-ubiquitylation step in p53 degradation. Rather than
representing a single functional domain, different parts of the acidic region perform separate func-
tions in p53 degradation, suggesting that it might be possible to therapeutically target them inde-
pendently.
Structured summary of protein interactions:
MDM2 physically interacts with S6b by anti bait coimmunoprecipitation (View interaction)
MDM2 physically interacts with p53 by anti bait coimmunoprecipitation (View interaction: 1, 2)
MDM2 physically interacts with C8a by anti bait coimmunoprecipitation (View interaction: 1, 2)
YY1 physically interacts with MDM2 by anti bait coimmunoprecipitation (View interaction)
MDM2 physically interacts with S6a by anti bait coimmunoprecipitation (View interaction)
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Tumour suppressor p53 has a key role in the regulation of
cellular responses to various types of stress, such as DNA damage,
hypoxia, nutrient deprivation, ribosomal stress, telomere erosion,
and oncogene activation [1]. p53 activity is kept under tight con-
trol in unstressed cells by a number of cellular factors, of which
Mdm2 and MdmX (Mdm4) seem to be critical for controlling p53
stability and activity during embryonic development and in nor-
mal somatic cells [2–6]. However, overexpression of Mdm2 or
MdmX found in some tumours can lead to a loss of p53 regulatory
function in cancer cells. It has been estimated that world-wide up
to 2.3 million new cancer cases each year could have p53 inacti-
vated due to the increased expression levels of Mdm2 or MdmX,
including a signiﬁcant fraction of lung, breast, colon, stomach,
and liver tumours [7].
Even though Mdm2 and MdmX show signiﬁcant homology and
share common domain architecture, each of them adopts a differ-chemical Societies. Published by E
).
k.ent strategy to suppress p53 function. While Mdm2 serves as a
RING ﬁnger ubiquitin ligase, i.e. mediates the interaction between
p53 and the E2 enzyme of the ubiquitylation pathway, and targets
p53 for degradation in 26S proteasome, the main function of
MdmX, whose RING domain lacks the E3 ubiquitin ligase activity,
seems to be a direct inhibition of p53 transcriptional activity
[8–10]. Nevertheless, we and others have shown that MdmX can
also directly contribute to p53 ubiquitylation and degradation
when dimerized with Mdm2 [11–13].
The Mdm2 ubiquitin ligase activity towards p53 requires the C-
terminal RING ﬁnger domain, an N-terminal p53-binding domain,
and a central region rich in acidic amino acids, often referred to
as the acidic domain (AD) [14–16]. While the exact role of this cen-
tral region ofMdm2 in p53 degradation remains unclear, it has been
identiﬁed as the binding site for numerous regulators of Mdm2
activity. The positive regulators of Mdm2 activity binding to this re-
gion include for example transcription factor YY1 and transcription
co-activator p300, both of which enhance p53 ubiquitylation by
Mdm2 [17–19]. The negative regulators include tumour suppressor
p14ARF, the expression of which is induced by oncogene activation
[20–23], the PML tumour suppressor [24] and ribosomal proteins
L5, L11, L23 and S27a that inhibit Mdm2 activity towards p53 inlsevier B.V. All rights reserved.
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gesting that AD may be directly involved in Mdm2-mediated p53
ubiquitylation [15,16]. However, many of these results were ob-
tained using long deletionswithinMdm2 or by exchanging large re-
gions between Mdm2 and MdmX, and these could potentially
change the overall conformation of the protein and inﬂuence the
activity of other Mdm2 domains, including the N-terminal p53-
binding domain and the RING domainwhere the E3 ubiquitin ligase
activity resides. In this study, we created a series of short deletions
within human Mdm2 covering the full length of the acidic domain
and tested the activity of themutants in cell-based p53 degradation
and ubiquitylation assays to identify regions within the acidic do-
main contributing to Mdm2 activity towards p53.
2. Materials and methods
2.1. Cell culture
U2OS and HEK293T cells were cultured at 37 C, 5% CO2 in
DMEM supplemented with 10% FBS, 2 mM L-glutamine, 50 U/ml
penicillin G and 50 lg/ml streptomycin sulphate.
2.2. Plasmids and mutagenesis
Plasmids coding for FLAG-tagged human p53, wild-type Mdm2
(pCHDM1A) and Mdm2 mutants C464A and 1-440 (Mdm2D441-
91) have been described previously [30–32]. Plasmids coding for
Mdm2 mutant D245-95, FLAG-tagged YY1, myc-tagged MdmX,
V5-tagged 19S proteasome subunits S4, S5a, S6a, and S6b, and
myc-tagged 20S proteasome subunit C8a were kindly provided
by Mary Hanlon, Johan Ericsson, Donna George, Christine Blattner,
and Michael Olson, respectively. Mdm2 mutants were derived by
site-directed mutagenesis using Pfu DNA polymerase (Stratagene)
and veriﬁed by DNA sequencing.
2.3. MDM2-mediated degradation of p53 and MdmX
U2OS cells in 60-mm dishes were transfected with 0.5 lg of
FLAG-p53 and 5 lg of wild type or mutant Mdm2 using Lipofect-
amine 2000 reagent (Invitrogen). Each transfection mixture con-
tained 0.5 lg of pEGFP-N1 (Clontech) to control for transfection
efﬁciency, and an empty plasmid pcDNA3.1 (Invitrogen) was used
to bring the total amount of transfected DNA to 6 lg. Cell were cul-
tured for 24 h, washed in PBS and lysed with 0.25 ml of SDS sample
buffer. Proteins were resolved by SDS–PAGE, transferred onto
nitrocellulose and detected using anti-FLAG M2 (Sigma–Aldrich,
IL, USA), anti-Mdm2 Ab-1 (Calbiochem), and anti-GFP 7.1/13.1
(Roche) antibodies. For MdmX degradation, myc-MdmX plasmid
construct was co-transfected with Mdm2 mutants at 1:1 ratio
and MdmX protein levels on Western blots were detected using
anti-myc 9E10 antibody.
2.4. MDM2-mediated p53 ubiquitylation
U2OS cells in 60-mm dishes were transfected with 0.75 lg of
FLAG-p53, 1 lg of HA-tagged ubiquitin and 4.25 lg of Mdm2 (or
Mdm2 mutants) using Lipofectamine 2000 and cultivated for fur-
ther 24 h. Cells were treated for 3 h with proteasome inhibitor
MG132 (10 lM) and lysed in 0.3 ml 0.5% SDS. Lysates were boiled
for 5 min, vortexed, cooled down and diluted with 1 ml Triton X-
100 lysis buffer (1% Triton X-100, 150 mM NaCl and 50 mM Tris
pH 8.0). Ubiquitylated p53 was immunoprecipitated using 1 lg
of DO-1 antibody (kindly provided by B. Vojtesek) and detected
by Western blotting using anti-HA Y11 antibody (Santa Cruz Bio-
technology). p53 and Mdm2 levels in inputs were detected using
DO-1 and anti-Mdm2 Ab-1 antibodies.2.5. MDM2 autoubiquitylation
U2OS cells in 60-mm dishes were transiently transfected with
5 lg of Mdm2 and 1 lg of vector encoding HA-tagged ubiquitin
using Lipofectamine 2000 and cultivated for further 24 h. Cells
were treated for 3 h with MG132 (10 lM) and lysed in 0.3 ml
0.5% SDS. Lysates were boiled for 5 min, vortexed, cooled to room
temperature and diluted with 1 ml Triton X-100 lysis buffer. Ubiq-
uitylated Mdm2 was immunoprecipitated using 1 lg of anti-
Mdm2 Ab-1 antibody and detected using anti-HA antibody Y11.
Mdm2 levels in the input were detected using Ab-1 antibody.
2.6. Immunoprecipitations
HEK293T cells in 100-mm plates were transfected with 6 lg of
DNA using Lipofectamine 2000 reagent (Invitrogen) and 24 h post-
transfection treated with MG132 for 4 h. Cells were lysed in ice-
cold Triton X-100 lysis buffer containing protease inhibitors (Com-
plete Mini EDTA-free; Roche). Immunoprecipitations were per-
formed overnight at 4 C with 1 lg of anti-Mdm2 Ab-1 or Ab-2,
anti-p53 DO-1 and CM-1, anti-myc 9E10 or anti-FLAG M2 agarose
(Sigma–Aldrich). Immunoprecipitated proteins were resolved
using SDS–PAGE and analysed by Western blotting using anti-
Mdm2 Ab-1, anti-myc 9E10, anti-p53 DO-1 or CM-1, and anti-V5
rabbit polyclonal (Sigma–Aldrich) antibodies.
3. Results and discussion
3.1. Only a minor part of the conserved acidic domain of Mdm2 is
indispensable for p53 degradation
Several studies have shown that the central region of Mdm2
plays a critical role in p53 degradation, possibly by inﬂuencing
the ability of Mdm2 to ubiquitylate p53 [14–16]. The importance
of the acidic region for Mdm2 function is supported by the fact that
its primary amino acid sequence is evolutionary extremely con-
served in mammals (Fig. 1A). On the other hand, the majority of re-
sults indicating that intact AD might be required for p53
degradation were obtained using relatively long deletions within
Mdm2 or by exchanging large protein parts between Mdm2 and
MdmX [14–16]. However, extensive mutations could potentially
change the overall conformation of the protein and inﬂuence the
function of other Mdm2 domains, such as the N-terminal p53-
binding domain or the C-terminal RING ﬁnger domain, where the
E3 ubiquitin ligase activity of Mdm2 resides. For example, we have
seen repeatedly that a deletion of a larger part (approx. 50 amino
acids) of AD changes the migration pattern of Mdm2 in a denatur-
ing SDS–PAGE gel to a much larger extent than a similar size dele-
tion at the C-terminus of the protein (Fig. 1B), suggesting the
possibility of a signiﬁcant impact of the AD deletion on the overall
structure of the Mdm2 protein. In order to study the role of the
central region in p53 degradation systematically and to minimize
possible effects on other Mdm2 domains, we divided the acidic do-
main into twelve separate parts of four to eight amino acids (de-
noted AD1 to AD12), fully covering the length of the domain
from the amino acid residue at position 218 to the residue at posi-
tion 296, and created a series of short non-overlapping deletions by
mutating each of the parts individually (Fig. 1C).
We tested the activity of the deletion mutants in a cell-based
p53 degradation assay to identify parts of AD required for Mdm2
activity towards p53. Only three deletion mutants (two adjacent
mutants DAD5 and DAD6 targeting amino acids 247–258, and a
separate deletion DAD9 of amino acids 270–274) were severely
impaired in their ability to target p53 for degradation (Fig. 2A).
The three mutations together covered less than 25% of the total
Fig. 1. Mdm2 AD is highly conserved in mammals. (A) The primary AD sequences were aligned using BOXSHADE 3.21 (http://www.ch.embnet.org/software/BOX_form.html).
(B) Deletions of comparable size in the acidic and RING domains of human Mdm2 have different impact on protein migration in SDS–PAGE. (C) A series of short deletions and
substitutions created within AD of human Mdm2.
Fig. 2. Identiﬁcation of regions within AD required for Mdm2-mediated p53
degradation. Activity of Mdm2 deletion mutants (A) and Mdm2 point mutants (B)
was tested in a cell-based p53 degradation assay. Activity of Mdm2 deletion
mutants in p53 and MdmX degradation assays (C).
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has to be intact for Mdm2 to mediate p53 degradation. The major-
ity of the domain did not seem to be directly involved in p53 deg-
radation. Such result was rather surprising, taking into account the
high degree of evolutionary conservation of the domain as a whole,
not just the regions that we identiﬁed as critical for p53 degrada-
tion (Fig. 1A). The observed identity of nearly 90% in the amino acid
sequence between human and mouse acidic domains indicates
that the whole domain is extremely important for Mdm2 function
in mammalian cells, possibly reﬂecting the fact that in addition to
the regulation of Mdm2 activity towards p53, AD has been impli-
cated in processes such as ubiquitylation-independent inhibition
of the DNA binding function of p53 [33] or a negative regulation
of p300-mediated p53 acetylation by Mdm2 [34]. Moreover,
Mdm2 has been reported to have other, p53-independent func-
tions in the control of cell cycle, differentiation, DNA repair, and
cell fate and the central acidic region might contribute to their
deregulation in cancer cells overexpressing Mdm2 [35,36].Although the p53 degradation-deﬁcient DAD5, DAD6, and
DAD9 deletion mutants did not show a signiﬁcantly changed
migration pattern on SDS–PAGE when compared to wild type
Mdm2, nor did they accumulate in transiently transfected cells
due to enhanced stability (Fig. 2A), we decided to further test the
above presented results using two additional point mutants AD5-
A and AD9-A in which all acidic amino acids residues in the corre-
sponding part of AD were exchanged for alanine residues rather
than deleted (Fig. 1C). The activity of the two point mutants
towards p53 was impaired, independently conﬁrming the involve-
ment of both identiﬁed regions in p53 degradation (Fig. 2B). The
defect in Mdm2-mediated p53 degradation could not be compen-
sated in trans by a co-expression of the two groups of mutants
together (DAD5 +DAD9), suggesting that both regions have to be
intact and present on the same Mdm2 molecule for p53 degrada-
tion to take place (Fig. 2C). At the same time, the observed defect
in targeting proteins for degradation was speciﬁc for p53 as an-
other Mdm2 substrate, MdmX, was efﬁciently degraded in the
presence of the AD5 and AD9 mutants already at 1:1 ratio.
3.2. Dual role of the Mdm2 acidic domain in p53 degradation
The E3 ubiquitin ligase activity of Mdm2 resides within the C-
terminal RING ﬁnger domain and early reports suggested that
the function of the acidic domain in p53 degradation might be
E3-independent [37,38]. On the other hand, later studies have
implicated the central part of Mdm2 also in the process of p53
ubiquitylation [15,16,39]. This apparent contradiction might actu-
ally reﬂect the use of different Mdm2 mutants or differences in the
experimental setup in these studies. We analysed the ability of our
short p53 degradation-deﬁcient mutants to mediate p53 ubiquity-
lation in vivo, in a cell-based assay. To our surprise, mutations of
different parts of the acidic domain had a differential impact on
Mdm2-mediated p53 ubiquitylation (Fig. 3A). Mutations targeting
amino acids 247–258 (regions AD5 and AD6) impaired the ability
of Mdm2 to mediate p53 ubiquitylation, while mutants targeting
amino acids 270–274 (region AD9) induced levels of p53 ubiquity-
lation similar to those induced by wild type Mdm2, indicating that
their defect in p53 degradation was not a result of their inability to
induce p53 ubiquitylation. At the same time, both groups of Mdm2
mutants were capable of autoubiquitylation (Fig. 3B), suggesting
that the E3 function of the C-terminal RING ﬁnger domain was
not inhibited by mutations introduced into the central part of the
protein.
Fig. 4. Phosphorylation sites within AD that were reported to potentially inﬂuence Mdm2 activity towards p53 cluster to regions identiﬁed in this study as being critical for
p53 degradation.
Fig. 3. AD mutants inactive in p53 degradation assays differ in their ability to mediate p53 ubiquitylation. Activity of selected AD mutants was tested in cell-based
ubiquitylation assays: (A) p53 ubiquitylation, (B) Mdm2 auto-ubiquitylation.
Fig. 5. Mdm2–p53 interaction outside the N-terminal binding domains is not impaired in inactive AD mutants. Interaction between AD mutants and p53DI mutant lacking
conserved N-terminal box I was tested. Mdm2–p53 complexes were immunoprecipitated with (A) anti-Mdm2 or (B) anti-p53 antibodies. (C) Inactivating AD mutations were
created in the context of the Mdm2D58-89 deletion mutant and p53DI-Mdm2D58-89 complexes were precipitated using anti-Mdm2 and anti-p53 antibodies. Mdm2D58-
89:D9, lacking the C-terminal tail, was used as a control.
2228 P. Dolezelova et al. / FEBS Letters 586 (2012) 2225–2231Interestingly, a study by Blattner et al. [40] showed that p53
ubiquitylation by mouse Mdm2 and p53 degradation can be
uncoupled by mutating serine residues in Mdm2 at positions
corresponding to S246, S253, S256, S260 and S262 of the human
protein into alanine residues, supporting the idea that a post-ubiq-
uitylation function for Mdm2 in p53 degradation may exist, andsuggesting that phosphorylation within AD might take part in
the regulation of Mdm2 activity towards p53. Other studies
showed that phosphorylation of serine residues in AD at positions
242, 256, 260, and 269 by several protein kinases, including GSK-3,
PLK1, and CK2, stimulates Mdm2-mediated degradation of p53
[41–43]. In contrast, Mdm2 phosphorylation at tyrosine 276 in
Fig. 6. The inactivity of AD9 mutant towards p53 is not caused by defects in its binding to proteasome. Mdm2DAD9 mutant retained the ability to form complexes with (A)
19S proteasome subunits S5a, S6a, and S6b, (B) 20S proteasome subunit C8a.
Fig. 7. Inactive AD mutants retain the ability to form complexes with YY1. Wild
type Mdm2 or Mdm2 deletion mutants were co-expressed with Flag-tagged YY1
and Mdm2–YY1 protein complexes were immunoprecipitated using anti-Flag M2
agarose.
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had the opposite effect, leading to increased binding of the
Mdm2 regulator p14ARF and decreased p53 turnover [44]. The fact
that amino acid residues targeted by these kinases in AD cluster
within the regions identiﬁed in this study as being critical for
Mdm2 activity towards p53 or within their close proximity
(Fig. 4) suggests that speciﬁc phosphorylation events modulate
Mdm2 activity towards p53 by inﬂuencing the function of the re-
gions identiﬁed in this study.
3.3. Mdm2–p53 binding is not impaired in inactive Mdm2 acidic
domain mutants
Physical interaction between Mdm2 and p53 is mediated
mainly by binding domains located at their respective N-termini.
However, several studies showed that the central region of
Mdm2 contains an additional site contributing to p53 binding
and p53 degradation [39,45–47]. We hypothesized that a defect
in Mdm2–p53 binding outside their N-terminal interaction do-
mains could provide an explanation for the observed inactivation
of our Mdm2 mutants. We therefore tested the ability of the AD
mutants to bind p53 in the context of proteins containing deletions
disrupting the N-terminal binding sites: Mdm2D58-89, lacking
critical amino acids 58–89 of the p53-binding domain, and
p53DI, lacking a conserved box I involved in Mdm2 binding.
Surprisingly, neither the short deletion mutants nor the point mu-
tants exhibited in our tests any signiﬁcant decrease in their capa-
bility to interact with p53 outside the main binding sites (Fig. 5),
suggesting that p53 binding may not be the only function for the
Mdm2 acidic domain in p53 ubiquitylation and degradation. Onthe other hand, we cannot exclude the possibility that two or more
separate p53 binding sites capable of independently mediating the
interaction with p53 in our binding assays may be present within
AD. Interestingly, incremental changes in the amount of p53 bound
to Mdm2 have been observed by Kulikov et al. in an experiment
analysing the effect of several different 25–40 amino acid deletions
within the acidic domain [45]. While these observations could be
explained by a differential effect of the deletions on the conforma-
tion and function of a single p53 binding site, the presence of two
or more p53 binding sites within the acidic domain could also
provide a plausible explanation. Additional studies on the mode
of p53 binding to the central region of Mdm2 and information
about the structure of the p53–AD complex will be necessary for
a more precise determination of possible molecular defects in the
binding of our acidic domain mutants to p53.
3.4. Acidic domain mutations inhibiting p53 degradation do not
disrupt the interaction between Mdm2 and the proteasome
Transport of ubiquitylated proteins to the proteasome is an
important step in ubiquitin-mediated proteolysis. Recent work
by Kulikov et al. [48] showed that Mdm2 promotes the formation
of a ternary complex with p53 and the proteasome. Mdm2 binds
several subunits of the 19S proteasome regulatory particle but it
also associates with larger protein complexes containing the a7
(C8a) subunit of the 20S proteasome. While the interactions of
Mdm2 with the proteasome occur through binding sites located
at the N- and C-termini of the protein, the central acidic domain
seems to be involved in the regulation of Mdm2–proteasome
complex formation. We therefore tested whether the observed
uncoupling of p53 degradation from p53 ubiquitylation caused
by AD9 mutations could be linked to a defect in their interaction
with proteasome. However, we did not detect any decrease in
the binding of the DAD9 mutant to 19S proteasome subunits S5a,
S6a and S6b, or the 20S proteasome subunit C8a in immunoprecip-
itation assays (Fig. 6), indicating that the AD9 mutants retain a
normal capacity to form complexes with the proteasome.
3.5. Analysis of the possible role of acidic domain binding to positive
regulators of Mdm2 E3 activity
Yin Yang 1 (YY1) and p300, both capable of enhancing Mdm2-
mediated ubiquitylation of p53, are the most important positive
regulators of Mdm2 activity towards p53 identiﬁed so far, which
can bind to the central region [17–19,49]. Protein YY1 has been
reported to physically interact with both Mdm2 and p53 and to
stabilize the Mdm2–p53 complex and we therefore tested whether
the acidic domain regions identiﬁed in this study might be essen-
tial for its binding. Results presented in Fig. 7 suggest that neither
AD5 nor AD9 is required for Mdm2–YY1 physical interaction.
Fig. 8. Mdm2 acidic domain regions required for p53 degradation are conserved in mammals but only partially conserved in Invertebrates. Mdm2 AD sequences were aligned
using BOXSHADE 3.21.
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was previously shown to be capable of mediating p53 ubiquityla-
tion but not degradation [38]. In our study, we covered this region
(amino acids 218–246) with four shorter deletions DAD1, DAD2,
DAD3, and DAD4, none of which had a signiﬁcant impact on
Mdm2-mediated p53 degradation (Fig. 2).
3.6. Acidic domain regions required for p53 degradation in mammals
are only partially conserved in Invertebrates
Mdm2-like proteins retaining many conserved features charac-
teristic for mammalianMdm2 have recently been identiﬁed in low-
er animals, including Arachnid Ixodes scapularis and a very simple
multicellular Placozoan Trichoplax adherens [50,51]. The acidic do-
main region identiﬁed by us as critically important for efﬁcient
Mdm2-mediated p53 ubiquitylation (amino acids 247–258 of hu-
manMdm2 protein) appears to bewell conserved also in lower Ver-
tebrates (e.g. in ﬁsh Danio rerio) and partially conserved in
Arachnids and Placozoans (Fig. 8). In contrast to that, the second
functionally important region identiﬁed in this study (correspond-
ing to amino acids 270–274 of human Mdm2) seems to be only
poorly conserved in the ﬁsh Mdm2 protein and completely missing
at the corresponding position in Invertebrate acidic domain se-
quences, suggesting that mechanisms of p53 regulation by Mdm2
might differ in mammals and lower animals. Alternatively, another
part of the acidic domain could be preferentially utilized in the
post-ubiquitylation step in p53 degradation in lower animals.
Taken together, we performed a systematic and comprehensive
mutational analysis of the conserved central acidic region of Mdm2
and our results indicate that only a minor part of the acidic domain
of Mdm2 is directly involved in p53 degradation. Other conserved
regions within this domain might participate in the regulation of
Mdm2 activity towards p53 or could be involved in some of the re-
ported p53-independent activities of Mdm2. Our data indicate that
the acidic domain plays a dual role in p53 degradation with differ-
ent parts of the domain having separate functions, rather than
forming a single functional domain. These results suggest that it
might be possible to therapeutically target their functions inde-
pendently to achieve a more efﬁcient Mdm2 inhibition and full
reactivation of p53 tumour suppressive activity in cancers express-
ing very high levels of Mdm2.
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